Skip Navigation LinksHome > December 2011 - Volume 30 - Issue 12 > Response to Primary and Booster Vaccination With 10-valent P...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31822a8541
Online-Only: Original Studies

Response to Primary and Booster Vaccination With 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Korean Infants

Kim, Chang-Hwi MD*; Kim, Jung Soo MD; Cha, Sung-Ho MD, PhD; Kim, Kwang-Nam MD§; Kim, Jong-Duck MD; Lee, Kyung Yil MD; Kim, Hwang Min MD**; Kim, Jong-Hyun MD; Hyuk, Sang Ma MD††; Hong, Jung-Yun MD‡‡; Park, Su Eun MD§§; Kim, Yun-Kyung MD¶¶; Kim, Nam Hee MD‖‖; Fanic, Aurélie MSc***; Borys, Dorota MD***; Ruiz-Guiñazù, Javier MD***; Moreira, Marta MD***; Schuerman, Lode MD***; Kim, Kyung-Hyo MD†††

Collapse Box


Background: This randomized single-blind study in Korea evaluated noninferiority of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus the 7-valent pneumococcal conjugate vaccine (7vCRM) when both were coadministered with H. influenzae type b (Hib) conjugate vaccine, as opposed to coadministration with diphtheria-tetanus-acellular pertussis-based combination vaccines in previous studies.

Methods: Infants received 3 primary doses at 2, 4, and 6 months and a booster dose at 12 to 18 months of PHiD-CV (N = 374) or 7vCRM (N = 129), both coadministered with Hib vaccine. Immune responses were measured 1 month postdose 3 and postbooster using 22F-inhibition enzyme-linked immunosorbent assay and functional opsonophagocytic activity assay.

Results: PHiD-CV-induced antibody responses against each of the vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM was demonstrated for all 10 PHiD-CV serotypes in terms of percentages of subjects reaching an antibody concentration ≥0.2 μg/mL after primary vaccination. Postprimary and postbooster, percentages of subjects with antibody concentration ≥0.2 μg/mL or opsonophagocytic activity titer ≥8 were generally consistent between groups for each pneumococcal serotype common to both vaccines. The safety and reactogenicity profiles of PHiD-CV and 7vCRM were generally comparable after both primary and booster vaccination.

Conclusions: In this Korean study, 3-dose PHiD-CV priming followed by a booster dose was immunogenic for all 10 vaccine pneumococcal serotypes and protein D. Noninferiority to 7vCRM in terms of enzyme-linked immunosorbent assay threshold responses postpriming was demonstrated. The safety and reactogenicity profiles of both vaccines when coadministered with Hib vaccine were generally comparable.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.